TABLE 1.
Patient Characteristics at Enrollment
| Characteristic | Data |
| Sequential cohort (n = 8) | |
| Age (y) | 55 (44–74) |
| Duration of metastatic disease (y) | 5 (2–12) |
| Prior chemotherapy regimens (neoadjuvant, adjuvant, metastatic) | 3.5 (1–9) |
| Prior endocrine regimens | 4.5 (2–6) |
| Number of lesions | 5 (2–9) |
| Sites of disease | |
| Soft tissue or bone | 6 (75%) |
| Includes visceral disease (lung or liver lesions) | 2 (25%) |
| Average 18F-FDG SUVmax* | 4.7 (3.6–9.9) |
| Average 18F-fluoroestradiol SULmean* | 1.3 (0.6–4.0) |
| Average 18F-fluoroestradiol SUVmax | 3.3 (1.9–7.6) |
| Simultaneous cohort (n = 15) | |
| Age (y) | 65 (32–76) |
| Duration of metastatic disease (y) | 4 (0.5–10) |
| Prior chemotherapy regimens (neoadjuvant, adjuvant, metastatic) | 4 (2–10) |
| Prior endocrine regimens | 3 (2–5) |
| Number of lesions | 7 (1–10) |
| Sites of disease | |
| Soft tissue only | 2 (13%) |
| Soft tissue or bone | 6 (40%) |
| Includes visceral disease (lung or liver lesions) | 7 (47%) |
| Average 18F-FDG SUVmax* | 5.2 (2.7–12.8) |
| Average 18F-fluoroestradiol SULmean* | 1.2 (0.4–3.9) |
| Average 18F-fluoroestradiol SUVmax | 3.2 (0.9–10.1) |
*
Geometric mean of up to 3 lesions with highest 18F-FDG SUVmax.
Qualitative data are numbers followed by percentages in parentheses; continuous data are median followed by range in parentheses.